Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Timber Pharmaceuticals, Inc.BPMX · Entity 110330 | Pres and CEO | June 12, 2019 | June 14, 2019 |
| ZEVRA THERAPEUTICS, INC.ZVRA · Entity 5212 | Director | March 09, 2023 | March 13, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Timber Pharmaceuticals, Inc.
Report date June 12, 2019 · Filed June 14, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.84 · Expires 2029-06-12 | Direct | 360,000 |
Reported balance
After 2019-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-12 · Grant · Acquired 360,000 · Balance 360,000 F1: This option vests and becomes exercisable ratably over 36 months |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests and becomes exercisable ratably over 36 months
ZEVRA THERAPEUTICS, INC.
Report date March 09, 2023 · Filed March 13, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,835 |
Reported balance
After 2023-03-09 transaction · row 1
1 source rowRow 1 · 2023-03-09 · Purchase · Acquired 5,000 · Balance 10,835 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.11 to $4.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.11 to $4.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CATALYST PHARMACEUTICALS, INC.
Report date July 15, 2026 · Filed July 17, 2026
Section 16 reporting ended · disclosed 2026-07-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Disposition to issuer · Disposed 383,314 · Balance 0 F1: The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger") |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $4.64 · Expires 2026-12-02 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-15 · Disposition to issuer · Disposed 33,500 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5: Each Option was fully vested. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $3.42 · Expires 2027-12-30 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-15 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5: Each Option was fully vested. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $7.07 · Expires 2028-12-28 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-15 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5: Each Option was fully vested. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $18.59 · Expires 2029-12-27 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-15 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5: Each Option was fully vested. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $14.15 · Expires 2030-12-08 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-15 · Disposition to issuer · Disposed 29,524 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $21.12 · Expires 2031-11-21 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-15 · Disposition to issuer · Disposed 23,248 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $22.77 · Expires 2032-11-20 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-07-15 · Disposition to issuer · Disposed 18,115 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2026-12-08 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-07-15 · Disposition to issuer · Disposed 1,414 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2027-11-21 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-07-15 · Disposition to issuer · Disposed 1,894 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2028-11-20 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-07-15 · Disposition to issuer · Disposed 5,468 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger")
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option.
F4: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU.
F5: Each Option was fully vested.
F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerRestricted Stock Units · Derivative | 5,468 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-26-000184 · form4.xml · derivative · entry 11 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,468 shares Expires 2028-11-20 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · kind: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F6 · derivative.exercise_date: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerRestricted Stock Units · Derivative | 1,894 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-26-000184 · form4.xml · derivative · entry 10 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,894 shares Expires 2027-11-21 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · kind: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F6 · derivative.exercise_date: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerRestricted Stock Units · Derivative | 1,414 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-26-000184 · form4.xml · derivative · entry 9 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,414 shares Expires 2026-12-08 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · kind: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F6 · derivative.exercise_date: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerOptions to purchase common stock · Derivative | 18,115 | $0.00 Strike: $22.77 | $0.00 |
DisclosureSEC source: 0001161697-26-000184 · form4.xml · derivative · entry 8 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,115 shares Expires 2032-11-20 F3 · kind: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F6 · derivative.exercise_date: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerOptions to purchase common stock · Derivative | 23,248 | $0.00 Strike: $21.12 | $0.00 |
DisclosureSEC source: 0001161697-26-000184 · form4.xml · derivative · entry 7 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,248 shares Expires 2031-11-21 F3 · kind: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F6 · derivative.exercise_date: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerOptions to purchase common stock · Derivative | 29,524 | $0.00 Strike: $14.15 | $0.00 |
DisclosureSEC source: 0001161697-26-000184 · form4.xml · derivative · entry 6 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,524 shares Expires 2030-12-08 F3 · kind: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F6 · derivative.exercise_date: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerOptions to purchase common stock · Derivative | 15,000 | $0.00 Strike: $18.59 | $0.00 |
DisclosureSEC source: 0001161697-26-000184 · form4.xml · derivative · entry 5 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2029-12-27 F3 · kind: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerOptions to purchase common stock · Derivative | 20,000 | $0.00 Strike: $7.07 | $0.00 |
DisclosureSEC source: 0001161697-26-000184 · form4.xml · derivative · entry 4 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2028-12-28 F3 · kind: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerOptions to purchase common stock · Derivative | 30,000 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001161697-26-000184 · form4.xml · derivative · entry 3 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2027-12-30 F3 · kind: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerOptions to purchase common stock · Derivative | 33,500 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001161697-26-000184 · form4.xml · derivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,500 shares Expires 2026-12-02 F3 · kind: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerCommon Stock, par value $0.001 per share | 383,314 | $31.50 | $12,074,391.00 |
DisclosureSEC source: 0001161697-26-000184 · form4.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger") Read SEC document |
| December 29, 2025 Filed Dec 30, 2025 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 1,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-25-000496 · form4.xml · derivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,163 Underlying: Common Stock · 1,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F2 · derivative.exercise_date: Derivative securities vested in equal tranches, 1/3rd on December 27, 2023, 1/3rd on December 27, 2024 and 1/3rd on December 27, 2025. F3 · derivative.expiration_date: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The final tranche of shares was delivered on December 29, 2025. Read SEC document |
| December 29, 2025 Filed Dec 30, 2025 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, par value $0.001 per share | 1,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-25-000496 · form4.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 383,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 1,413 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-25-000451 · form4.xml · derivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,497 Underlying: Common Stock · 1,413 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F2 · derivative.exercise_date: Derivative securities vested in equal tranches, 1/3rd on December 8, 2024, 1/3rd on December 8, 2025 and 1/3rd on December 8, 2026. F3 · derivative.expiration_date: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The second tranche of shares was delivered on December 8, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, par value $0.001 per share | 1,413 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-25-000451 · form4.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 381,980 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 01:08 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 947 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-25-000424 · form4.xml · derivative · entry 4 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,910 Underlying: Common Stock · 947 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Shares of common stock will be delivered to the Reporting Person upon vesting. F4 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026, and 1/3rd on November 21, 2027. F5 · derivative.expiration_date: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on November 21, 2025. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 01:08 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, par value $0.001 per share | 947 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-25-000424 · form4.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| November 20, 2025 Filed Nov 25, 2025 01:08 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantRestricted Stock Units · Derivative | 5,468 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-25-000424 · form4.xml · derivative · entry 3 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,857 Underlying: Common Stock · 5,468 shares Expires not disclosed F3 · derivative.exercise_price: Shares of common stock will be delivered to the Reporting Person upon vesting. F2 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028. F3 · derivative.expiration_date: Shares of common stock will be delivered to the Reporting Person upon vesting. Read SEC document |
| November 20, 2025 Filed Nov 25, 2025 01:08 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 18,115 | $0.00 Strike: $22.77 | $0.00 |
DisclosureSEC source: 0001161697-25-000424 · form4.xml · derivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,389 Underlying: Common Stock · 18,115 shares Expires 2032-11-20 F2 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028. Read SEC document |
| August 27, 2025 Filed Aug 28, 2025 21:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionOptions to purchase common stock · Derivative | 50,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001161697-25-000302 · form4.xml · derivative · entry 3 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,274 Underlying: Common Stock · 50,000 shares Expires 2025-12-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Derivative securities vested in three annual tranches beginning on December 19, 2019. Read SEC document |
| August 27, 2025 Filed Aug 28, 2025 21:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | SaleCommon Stock, par value $0.001 per share | 26,000 | $20.20 | $525,200.00 |
DisclosureSEC source: 0001161697-25-000302 · form4.xml · nonDerivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 379,620 F1 · price: Shares were sold on the open market to fund the exercise price and estimated taxes due from Reporting Person as a result of the exercise of the stock options reported on Table II. F2 · price: Represents a weighted average sales price for the shares sold. Shares were sold in a range from $20.10 to $20.32 per share. Read SEC document |
| August 27, 2025 Filed Aug 28, 2025 21:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, par value $0.001 per share | 50,000 | $2.24 | $112,000.00 |
DisclosureSEC source: 0001161697-25-000302 · form4.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 405,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-25-000073 · form4.xml · derivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,274 Underlying: Common Stock · 4,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F2 · derivative.exercise_date: Derivative securities vested in equal tranches, 1/3rd on February 14, 2023, 1/3rd on February 14, 2024 and 1/3rd on February 14, 2025. F3 · derivative.expiration_date: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The final tranche of shares was delivered on February 14, 2025. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, par value $0.001 per share | 4,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-25-000073 · form4.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 355,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| December 27, 2024 Filed Dec 31, 2024 21:30 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 1,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-24-000545 · form4.xml · derivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,274 Underlying: Common Stock · 1,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F2 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on December 27, 2023, 1/3rd on December 27, 2024 and 1/3rd on December 27, 2025. F3 · derivative.expiration_date: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The second tranche of shares was delivered on December 27, 2024. Read SEC document |
| December 27, 2024 Filed Dec 31, 2024 21:30 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, par value $0.001 per share | 1,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-24-000545 · form4.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| December 09, 2024 Filed Dec 11, 2024 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 1,413 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-24-000509 · form4.xml · derivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,607 Underlying: Common Stock · 1,413 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F2 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on December 8, 2024, 1/3rd on December 8, 2025 and 1/3rd on December 8, 2026. F3 · derivative.expiration_date: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on December 9, 2024. Read SEC document |
| December 09, 2024 Filed Dec 11, 2024 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, par value $0.001 per share | 1,413 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-24-000509 · form4.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 22:01 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantRestricted Stock Units · Derivative | 2,841 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-24-000484 · form4.xml · derivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,020 Underlying: Common Stock · 2,841 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F1 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026 and 1/3rd on November 21, 2027. F3 · derivative.expiration_date: Shares of common stock will be delivered to the Reporting Person upon vesting. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 22:01 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 23,248 | $0.00 Strike: $21.12 | $0.00 |
DisclosureSEC source: 0001161697-24-000484 · form4.xml · derivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,179 Underlying: Common Stock · 23,248 shares Expires 2031-11-21 F1 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026 and 1/3rd on November 21, 2027. Read SEC document |
| August 22, 2024 Filed Aug 23, 2024 21:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionOptions to purchase common stock · Derivative | 15,000 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001161697-24-000375 · form4.xml · derivative · entry 3 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,931 Underlying: Common Stock · 15,000 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Options vested in three annual tranches beginning on January 2, 2019. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 21:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | SaleCommon stock, par value $0.001 per share | 15,000 | $20.10 | $301,455.00 |
DisclosureSEC source: 0001161697-24-000375 · form4.xml · nonDerivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 348,874 F1 · price: Shares were sold on the open market for personal reasons and not as a result of any disagreement with the Company. F2 · price: Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $20.00 to $20.485 per share. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 21:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon stock, par value $0.001 per share | 15,000 | $4.01 | $60,150.00 |
DisclosureSEC source: 0001161697-24-000375 · form4.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 363,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 21:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionOptions to purchase common stock · Derivative | 25,000 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001161697-24-000194 · form4.xml · derivative · entry 3 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,931 Underlying: Common Stock · 25,000 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Options vested in three annual tranches beginning on January 2, 2019. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 21:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | SaleCommon stock, par value $0.001 per share | 25,000 | $15.68 | $392,000.00 |
DisclosureSEC source: 0001161697-24-000194 · form4.xml · nonDerivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 348,874 F1 · price: Shares were sold on the open market to fund payment of a personal tax liability and not as a result of any disagreement with the Company. F2 · price: Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $15.55 to $15.77 per share. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 21:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon stock, par value $0.001 per share | 25,000 | $4.01 | $100,250.00 |
DisclosureSEC source: 0001161697-24-000194 · form4.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 373,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:01 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-24-000106 · form4.xml · derivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,931 Underlying: Common Stock · 4,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F2 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on February 14, 2023, 1/3rd on February 14, 2024 and 1/3rd on February 14, 2025. F3 · derivative.expiration_date: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The second tranche of shares was delivered on February 15, 2024. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:01 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, Par Value $0.001 per share | 4,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-24-000106 · form4.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 348,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 22:19 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionOptions to purchase common stock · Derivative | 10,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001161697-24-000027 · form4.xml · derivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,931 Underlying: Common Stock · 10,000 shares Expires 2024-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vested in three annual tranches beginning on January 3, 2018. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 22:19 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, Par Value $0.001 per share | 10,000 | $1.13 | $11,300.00 |
DisclosureSEC source: 0001161697-24-000027 · form4.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 344,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 1,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-23-000653 · form4.xml · derivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,931 Underlying: Common Stock · 1,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F2 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on December 27, 2023, 1/3rd on December 27, 2024 and 1/3rd on December 27, 2025. F3 · derivative.expiration_date: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on December 27, 2023. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, Par Value $0.001 per share | 1,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-23-000653 · form4.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 334,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionOptions to purchase common stock · Derivative | 50,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001161697-23-000623 · form4.xml · derivative · entry 3 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 244,264 Underlying: Common Stock · 50,000 shares Expires 2024-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Options vested in three annual tranches beginning on January 3, 2018. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | SaleCommon stock, par value $0.001 per share | 50,000 | $13.33 | $666,250.00 |
DisclosureSEC source: 0001161697-23-000623 · form4.xml · nonDerivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,541 F1 · price: Shares were sold on the open market for personal reasons, and to fund the exercise price for stock options expiring on January 3, 2024, and not as a result of any disagreement with the Company. F2 · price: Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $13.30 to $13.36 per share. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon stock, par value $0.001 per share | 50,000 | $1.13 | $56,500.00 |
DisclosureSEC source: 0001161697-23-000623 · form4.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 383,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantRestricted Stock Units · Derivative | 4,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-23-000618 · form4.xml · derivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 294,264 Underlying: Common Stock · 4,240 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F1 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on December 8, 2024, 1/3rd on December 8, 2025 and 1/3rd on December 8, 2026. F3 · derivative.expiration_date: Shares of common stock will be delivered to the Reporting Person upon vesting. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 29,524 | $0.00 Strike: $14.15 | $0.00 |
DisclosureSEC source: 0001161697-23-000618 · form4.xml · derivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,024 Underlying: Common Stock · 29,524 shares Expires 2030-12-08 F1 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on December 8, 2024, 1/3rd on December 8, 2025 and 1/3rd on December 8, 2026. Read SEC document |
| May 11, 2023 Filed May 12, 2023 21:01 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionOptions to purchase common stock · Derivative | 20,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001161697-23-000287 · form4.xml · derivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,500 Underlying: Common Stock · 20,000 shares Expires 2023-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option was granted on June 15, 2016 and previously vested in two annual installments. Read SEC document |
| May 11, 2023 Filed May 12, 2023 21:01 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon stock, par value $0.001 per share | 20,000 | $0.79 | $15,800.00 |
DisclosureSEC source: 0001161697-23-000287 · form4.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 05, 2023 Filed Apr 7, 2023 21:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionOptions to purchase common stock · Derivative | 30,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001161697-23-000243 · form4.xml · derivative · entry 3 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 280,500 Underlying: Common Stock · 30,000 shares Expires 2023-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted on June 15, 2016 and previously vested in two annual installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.